Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06562543 · ClinicalTrials.gov registry record · Phase 4
A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer
A Phase 4 study of Colorectal Cancer, sponsored by Takeda.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 78
- Enrollment target
- 20
- Study locations
NCT06562543 is a Phase 4 study of Colorectal Cancer that is actively recruiting participants, run by Takeda. The registered enrollment target is 78 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT06562543, a Phase 4 study of Colorectal Cancer, is actively recruiting participants, sponsored by Takeda.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 78 participants
- Enrollment target
- 20
- Study locations
Study Summary
High blood pressure (hypertension) is a known side effect of the treatment with fruquintinib. Current research does not provide a clear answer whether minority groups such as Black/African American and/or Hispanic/Latino with refractory metastatic colorectal cancer (mCRC) have a bigger risk of higher blood pressure after treatment with fruquintinib. The main aim of this study is to learn how often adults of a minority group experience hypertension after they have been treated with fruquintinib for refractory mCRC. Other aims are to learn how safe fruquintinib is and how well it is tolerated by participants. Participants will receive fruquintinib in 4-week treatment cycles until their condition worsens, they do no longer tolerate the treatment or stop the treatment for other reasons. After the last treatment, participants will be checked upon every 3 months until study completion.
Conditions Studied
Interventions
- DRUG Fruquintinib
Study Locations (20)
California
- University of California San Diego - La Jolla
- University of Southern California - Los Angeles
- PIH Health Whittier Hospital - Whittier
Florida
- University of Florida - Gainesville
- University of Miami - Miami
- Baptist Health - Miami Cancer Institute - Miami
Alabama
- Central Alabama Research - Birmingham
- University of Alabama at Birmingham - Birmingham
Arizona
- Ironwood Cancer and Research Centers - Chandler
- University of Arizona - Tucson
Louisiana
- Our Lady of the Lake Physician Group - LSU Health Baton Rouge Oncology - Baton Rouge
- Willis Knighton Cancer Center - Shreveport
Delaware
- Christiana Care Health Services - Newark
Georgia
- Emory University - Atlanta
Illinois
- Hope and Healing Cancer Services - Hinsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2025-01-14 |
| Est. Completion | 2027-10-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06562543
The ClinicalTrials.gov registry entry for NCT06562543 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Fruquintinib is the first listed.
NCT06562543 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT06562543 about?
NCT06562543 is a clinical study titled "A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer". High blood pressure (hypertension) is a known side effect of the treatment with fruquintinib. Current research does not provide a clear answer whether minority groups such as Black/African American and/or Hispanic/Latino with refractory metastatic colorectal cancer (mCRC) have a bigger risk of highe...
What is the current status of trial NCT06562543?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 78 participants. The study started on 2025-01-14. Estimated completion is 2027-10-04.
What conditions does trial NCT06562543 study?
This clinical trial studies the following conditions: Colorectal Cancer.
What interventions are being tested in trial NCT06562543?
The interventions under investigation include: Fruquintinib (DRUG).
Who is sponsoring clinical trial NCT06562543?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06562543 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Delaware, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Patient Satisfaction of Miralax and Gatorade Versus Movi Prep
COMPLETED · Phase 4
-
Intraoperative TAP Block With Bupivacaine/Dexamethasone Against Liposomal Bupivacaine (Exparel®)
COMPLETED · Phase 4
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
Resistance Exercise and Creatine in Colorectal Cancer
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.